- Home
- ASBP vs APM Comparison
ASBP vs APM Comparison
Compare ASBP & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASBP | APM |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 8.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ASBP | APM |
|---|---|---|
| Price | $1.54 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 69.3K |
| Earning Date | 02-24-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,941.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $0.69 |
| 52 Week High | $632.00 | $4.47 |
Technical Indicators
Market Signals| Indicator | ASBP | APM |
|---|---|---|
| Relative Strength Index (RSI) | 58.82 | 34.24 |
| Support Level | $1.44 | $0.80 |
| Resistance Level | $2.45 | $1.02 |
| Average True Range (ATR) | 0.34 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 61.73 | 11.50 |
Price Performance
Historical ComparisonAbout ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.